Fig.Ā 2From: A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosisClinical outcomes for localized soft tissue sarcomas with genomic sequencing treated at Stanford (nā=ā96). a Forest plot of most commonly altered 8 genes with prognosis reveals only CDKN2A to be significantly associated with worse prognosis. b KaplanāMeier plot of overall survival for CDKN2A altered vs. non-CDKN2A altered patients (pā=ā0.017). c Histologic distribution of all patients (d) and CDKN2A altered patients (C2) reveals increases in representation of MPNST, MFS, and UPS with decreases in LMS and LPS. e KaplanāMeier plot of time to recurrence for CDKN2A altered vs. non-CDKN2A altered patients (pā=ā0.09). f KaplanāMeier plot of time to treatment failure for first line systemic chemotherapy for CDKN2A altered vs. non-CDKN2A altered patients (pā=ā0.29)Back to article page